MarketPulse
T

$TERN

3 articles found
0 positive
0 negative
3 neutral
The Motley FoolThe Motley Fool··Jonathan Ponciano

Major Investor Trims $104M Nuvalent Stake as Cancer Drug Developer Surges 30%

Vestal Point Capital sold $103.93M in Nuvalent shares, reducing exposure despite company's 30% rally and $1.4B cash position awaiting 2026 FDA decisions.
ABBVNUVLTERNBMRNFDA approvalbiotech
The Motley FoolThe Motley Fool··Eric Trie

ORBIMED Advisors Reduces Terns Pharma Position Despite 858% Annual Gain

ORBIMED Advisors divested 5.4 million Terns Pharma shares worth $125 million despite the stock's 858% annual gain, reducing its stake as the biotech company advances clinical programs.
LLYTERNEWvaluationbiotech
The Motley FoolThe Motley Fool··Jonathan Ponciano

First Turn Management Establishes $35M Stake in Clinical-Stage Biotech Terns

First Turn Management invests $35M in clinical-stage biotech Terns Pharmaceuticals, acquiring 4.03% stake. Stock surged 826% year-over-year on cancer drug trial progress.
TERNdrug developmentstock surge